Stegent Equity Advisors Inc. Has $348,000 Holdings in Danaher Corporation $DHR

Stegent Equity Advisors Inc. boosted its position in Danaher Corporation (NYSE:DHR) by 60.5% in the second quarter, HoldingsChannel reports. The firm owned 1,764 shares of the conglomerate’s stock after buying an additional 665 shares during the quarter. Stegent Equity Advisors Inc.’s holdings in Danaher were worth $348,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Hills Bank & Trust Co grew its position in shares of Danaher by 0.3% during the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock valued at $3,693,000 after acquiring an additional 53 shares during the period. Worth Financial Advisory Group LLC grew its position in shares of Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after acquiring an additional 53 shares during the period. Sageworth Trust Co grew its position in shares of Danaher by 2.3% during the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock valued at $493,000 after acquiring an additional 54 shares during the period. 1834 Investment Advisors Co. grew its position in shares of Danaher by 3.3% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 54 shares during the period. Finally, Bruce G. Allen Investments LLC grew its position in shares of Danaher by 13.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after acquiring an additional 54 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Performance

Shares of DHR stock opened at $223.03 on Friday. The stock has a market capitalization of $157.54 billion, a P/E ratio of 45.99, a PEG ratio of 3.41 and a beta of 0.77. The company has a current ratio of 1.52, a quick ratio of 1.22 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is $202.73 and its 200 day moving average is $198.53. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the prior year, the company posted $1.71 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio is currently 26.39%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on DHR. Evercore ISI increased their target price on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Cowen reissued a “buy” rating on shares of Danaher in a research report on Wednesday. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research report on Tuesday, September 2nd. UBS Group dropped their price target on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. Finally, Barclays upped their price target on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday. Eighteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.